Featured - Local - Top Stories - April 28, 2021

Pharmaceutical Manufacturing Strategy to guarantee affordable medicines

Government has approved the Pharmaceutical Manufacturing Strategy 2021-2025, which is the first one in the history of Zimbabwe, is envisaged to facilitate the growth of the sector and guarantee affordable medicines for the citizens.

The strategy is set to increase production of essential medicines has been approved by government and it will resolve bottlenecks associated with  the pharmaceutical industry therefore boosting domestic and export markets.

Speaking at the post-cabinet press briefing Minister Of Information, Publicity And Broadcasting Services, Monica Mutsvangwa said the objectives of the Strategy include the following, to increase the market share of local pharmaceutical products from the current 12% to 35% by 2025; to increase local production of essential medicines from US$31.5 million to US$150 million by 2025; to increase local production of essential medicines from 30% to 60% by 2025; and to improve exports of pharmaceutical products from 10% to 25% by 2025.

“Cabinet acknowledged that the major challenge bedevilling the pharmaceutical sector was low production as a result of use of obsolete and antiquated equipment, cumbersome registration procedures and limited innovation.

“In order to increase production, Government institutions and hospitals will be encouraged to procure pharmaceutical products from Local manufacturers in line with the local Content Strategy,” Mutsvangwa said.

Increased production; enhancement of competitiveness; market expansion; production diversification; export development; improved ease of doing business; and mobilisation of the required financial resources are some of the measures that will be employed in order for the pharmaceutical sector to meet the set objectives.

“Competitiveness of the local pharmaceutical industry will be achieved through such measures as the use of raw materials that are exempted from import duties as well as Value Added Tax deferment,

“NatPharm will increase its capacity to procure locally manufactured pharmaceutical products. Furthermore, the Medicines Control Authority of Zimbabwe (MCAZ) will be capacitated to ensure faster registration of pharmaceutical products and to develop a programme on plant refurbishments, and upgrading and improvements in Quality Management Systems,” Mutsvangwa said.

This will ensure that the local manufacturers comply with international pharmaceutical manufacturing quality standards and enhance competitiveness locally and internationally.

 

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *

Check Also

Export incentives drive gold deliveries to record high in June

Zimbabwe’s export incentives have seen gold deliveries to Fidelity Printers and Refiners r…